CFO Terrance P. Coyne sold entire 64.4K share position in RPRX for $3.5M under pre-arranged 10b5-1 plan
Terrance P. Coyne, EVP & CFO, sold 64,399 shares of Royalty Pharma plc at $53.98 on 2026-05-26, liquidating his complete shareholding. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-02-24, meaning the sale was scheduled rather than discretionary. At the time of sale, RPRX traded at $53.98 against a current price of $54.48 and a 52-week high of $54.74, placing the transaction near the high end of the range. Coyne's prior trades at RPRX show mixed post-sale price performance: five preceding sales at this ticker yielded 30-day returns ranging from +2.4% to +9.2% and 90-day returns from +8.4% to +18.5%, while his broader cross-ticker track record across 20 prior sells averaged +7.0% 30-day and +16.6% 90-day returns. The company's fundamentals remain solid with $630.6M quarterly revenue, $294.7M net income, and +5.1% annual revenue growth, though the P/E of 25.58 reflects a mature valuation. The complete exit by a top finance executive warrants attention given his prior history at this ticker, though the scheduled nature of the trade precludes timing-based inference.
CFO Terrance Coyne sells nearly all RPRX shares in dual-tranche sale worth $1.73M near 52-week highs.
Coyne Terrance P., the company's Chief Financial Officer, liquidated his entire equity stake in Royalty Pharma across two transactions, divesting over $1.7 million in total value. The timing is noteworthy: the stock has rallied significantly in recent months and is currently trading near its 52-week highs, which is the opposite pattern from typical insider confidence-driven sales that usually occur during weakness or consolidation. Royalty Pharma is a profitable, revenue-growing business with solid fundamentals, so the sale doesn't signal financial distress at the company level. However, a CFO liquidating 100% of personal holdings at elevated valuations—rather than trimming positions gradually or during dips—suggests either portfolio rebalancing, estate planning, or a preference to reduce exposure at favorable pricing. This complete exit warrants monitoring to see whether other insiders follow suit or if the CFO's sales represent an isolated tax or personal liquidity event.
Add RPRX to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
